These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 8882383)

  • 21. Azithromycin for acute lower respiratory tract infections.
    Panpanich R; Lerttrakarnnon P; Laopaiboon M
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001954. PubMed ID: 18253999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bacteriological, pharmacokinetic and clinical evaluation of azithromycin in the pediatric field].
    Akita H; Sato Y; Kusumoto Y; Iwata S; Takeuchi Y; Aoyama T; Yokota T; Sunakawa K
    Jpn J Antibiot; 1996 Oct; 49(10):899-916. PubMed ID: 8986553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New developments in antibacterial choice for lower respiratory tract infections in elderly patients.
    Ferrara AM; Fietta AM
    Drugs Aging; 2004; 21(3):167-86. PubMed ID: 14979735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Azithromycin and clarithromycin: overview and comparison with erythromycin.
    Whitman MS; Tunkel AR
    Infect Control Hosp Epidemiol; 1992 Jun; 13(6):357-68. PubMed ID: 1320067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous azithromycin.
    Garey KW; Amsden GW
    Ann Pharmacother; 1999 Feb; 33(2):218-28. PubMed ID: 10084418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacological and pharmacokinetic properties of azithromycin (Zithromac), a novel 15-membered ring macrolide antibacterial agent].
    Matsunaga T
    Nihon Yakurigaku Zasshi; 2001 May; 117(5):343-9. PubMed ID: 11411344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.
    Vergis EN; Indorf A; File TM; Phillips J; Bates J; Tan J; Sarosi GA; Grayston JT; Summersgill J; YU VL
    Arch Intern Med; 2000 May; 160(9):1294-300. PubMed ID: 10809032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections.
    Hoepelman AI; Sips AP; van Helmond JL; van Barneveld PW; Neve AJ; Zwinkels M; Rozenberg-Arska M; Verhoef J
    J Antimicrob Chemother; 1993 Jun; 31 Suppl E():147-52. PubMed ID: 8396086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azithromycin: the first of the tissue-selective azalides.
    Hoepelman IM; Schneider MM
    Int J Antimicrob Agents; 1995 May; 5(3):145-67. PubMed ID: 18611663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study.
    Gris P
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():93-101. PubMed ID: 8818850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azithromycin--review of key chemical, pharmacokinetic and microbiological features.
    Lode H; Borner K; Koeppe P; Schaberg T
    J Antimicrob Chemother; 1996 Jun; 37 Suppl C():1-8. PubMed ID: 8818841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microbiological profile of telithromycin, the first ketolide antimicrobial.
    Felmingham D
    Clin Microbiol Infect; 2001; 7 Suppl 3():2-10. PubMed ID: 11523558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of dirithromycin and azithromycin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Cazzola M; Vinciguerra A; Di Perna F; Califano C; Calderaro F; Salzillo A; Centanni S
    J Chemother; 1999 Apr; 11(2):119-25. PubMed ID: 10326742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.
    Balfour JA; Benfield P
    Pharmacoeconomics; 1996 Aug; 10(2):164-78. PubMed ID: 10163419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythromycin, clarithromycin, and azithromycin: are the differences real?
    Amsden GW
    Clin Ther; 1996; 18(1):56-72; discussion 55. PubMed ID: 8851453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefuroxime axetil: an updated review of its use in the management of bacterial infections.
    Scott LJ; Ormrod D; Goa KL
    Drugs; 2001; 61(10):1455-500. PubMed ID: 11558834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications.
    Drew RH; Gallis HA
    Pharmacotherapy; 1992; 12(3):161-73. PubMed ID: 1319048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004.
    Melo-Cristino J; Santos L; Ramirez M;
    Rev Port Pneumol; 2006; 12(1):9-30. PubMed ID: 16572254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections.
    Darkes MJ; Perry CM
    Am J Respir Med; 2003; 2(2):175-201. PubMed ID: 14720016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.